Borealis Biosciences
BC - VancouverBiotechnology
Focus: Borealis Biosciences is a Vancouver-based early-stage biotech focused on RNA medicine for kidney disease, operating at Series A stage with a lean team of 1-50 employees. The company targets high-impact therapeutic areas in gene therapy and nephrology.
Profile data last refreshed 53m ago · AI intelligence enriched 2w ago
Funding Stage
SERIES A
Employees
1-50
Open Jobs
1
Should You Work at Borealis Biosciences?
AI assessmentBorealis is a speculative early-stage bet best suited for experienced researchers or operational leaders comfortable with pre-clinical risk and willing to invest sweat equity into an unproven RNA/nephrology platform.
Why Work Here
- Early-stage equity opportunity with exposure to RNA medicine, a high-growth modality attracting significant investor and Big Pharma interest.
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Open Jobs (1)
Interview Prep Quick Facts
Open Roles: 1 active job
Hiring Trend
Help build intelligence for Borealis Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.